Genfit

2023年6月22日

5天改變09:30am今天上午09:25 966年納什和纖維化患者斯蒂芬·a·哈裏森1皮埃爾•Bedossa 2辛西婭·d·家夥,3家m . Schattenberg, Rohit Loomba 4 5 Rebecca陶布6多米尼克Labriola 6山姆·e·穆薩7 w·內夫,8阿倫•j . Sanyal 9•馬讚Noureddin 10之一Meena邦薩爾,11 Naim Alkhouri 12弗拉德Ratziu13 1牛津大學,牛津大學,英國&頂峰臨床研究,聖安東尼奧,TX,美國;2平移和臨床研究所、醫學科學教師,紐卡斯爾大學,紐卡斯爾,英國;3杜克大學醫學中心,達勒姆,數控、美國;4大學醫學中心、美因茨、德國;加州大學聖地亞哥5拉霍亞,CA,美國;美國,6情歌製藥、肯肖霍肯PA;7亞利桑那大學醫學科學,圖森,亞利桑那州,美國;8約代謝專家,薩拉索塔,佛羅裏達州美國;9弗吉尼亞聯邦大學,裏士滿,弗吉尼亞州,美國;10休斯頓研究所,休斯頓,德克薩斯州,美國; 11Mt Sinai, New York, NY, USA; 12Arizona Liver Health, Tucson, AZ, USA; 13Pitie-Salpetriere Hospital, Institute of Cardiometabolism & Nutrition, Sorbonne Universite, Paris, France. Disclosures DISCLOSURES: I disclose the following financial relationship(s) with a commercial interest: Scientific advisor or consultant for Akero, Aligos, Altimmune, Arrowhead, Bluejay Therapeutics, Boxer Capital, Chronwell, Echosens, Enyo, Foresite Labs, Galectin, Galecto, Gilead, GSK, Hepagene, Hepion, Hepta Bio, HistoIndex, Humana, Intercept, Ionis, Madrigal, Medpace, NeuroBo Pharmaceuticals, Northsea, Novo Nordisk, Perspectum, Pfizer, Sonic Incytes, Sagimet, Terns, Viking. Stock options: Akero, Chronwell, Cirius, Galectin, Genfit, Hepion, Hepta Bio, HistoIndex, Metacrine, NGM Bio, Northsea, Sonic Incytes Grant/Research support: Akero, Altimmune, Axcella, BMS, Corcept, Cymabay, Enyo, Galectin, Genentech, Genfit, Gilead, GSK, Hepion, Hightide, Immuron, Intercept, Inventiva, Ionis, Madrigal, NGM Bio, Novartis, Novo Nordisk, Northsea, Pfizer, Poxel, Sagimet, Terns, Viking. Resmetirom Resmetirom is an oral, liver-targetedTHR-βselective agonist in development for NASH1 In patients with NASH, selectivity for THR-β may provide metabolic benefits of thyroid hormone that are mediated by the liver (reduction of excess hepatic fat & atherogenic lipids/lipoproteins), while avoiding negative systemic effects of excess thyroid hormone in heart & bone In the randomized, double-blind,placebo-controlled Phase 2 serial liver biopsy trial in adults with biopsy- confirmed NASH (NCT02912260), resmetirom treatment resolved NASH in a significantly greater percentage of patients & reduced liver enzymes, inflammatory biomarkers, & fibrosis compared with placebo2 MAESTRO-NASHis a randomized, double-blind,placebo-controlled Phase 3 serial liver biopsy trial evaluating the efficacy & safety of resmetirom in adults with biopsy-confirmed NASH (NCT03900429) Here we report Week 52 data in 966 patients with NASH & F1B, F2, or F3 fibrosis from the MAESTRO-NASH trial 1. Kelly MJ, et al. J Med Chem. 2014;57(10):3912-3923. 2. Harrison SA, et al. Lancet. 2019;394(10213):2012-2024 .